eXoZymes (EXOZ)

The company’s approach centres on cell-free biomanufacturing, using enzymes outside living cells to carry out controlled chemical conversions. This is intended to offer an alternative to traditional chemical synthesis, extraction from plants or other natural sources, and some forms of fermentation-based synthetic biology. By removing the need to grow and manage living organisms during production, eXoZymes aims to improve process control, scalability, and consistency for selected molecules.

Sustainability is a key part of the company’s investment case. Many natural-product chemicals are made through supply chains that can depend on agricultural land, petrochemical feedstocks, harsh reagents, or complex purification steps. eXoZymes seeks to create cleaner manufacturing pathways that may reduce waste, energy use, and environmental impact, while also improving supply reliability for customers.

As a listed biotechnology and specialty manufacturing company, eXoZymes is exposed to the opportunities and risks typical of platform businesses. Its long-term value depends on technical validation, commercial partnerships, production economics, regulatory requirements, and the ability to move from development-stage chemistry to reliable industrial-scale output.